Document:

Exhibit
10.20

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement (“Agreement”)
is made between Better Therapeutics, Inc., a Delaware corporation (the “Company”), and Kevin Appelbaum (the “Executive”)
and is effective as of April 6, 2021 (the “Effective Date”). Notwithstanding the foregoing, certain provisions of this
Agreement, as indicated below, shall not be effective until the Closing Date, as such term is defined in the Agreement and Plan of Merger
by and among the Company, Mountain Crest Acquisition Corp. II and MCAD Merger Sub Inc. (the “Merger Agreement”), dated
as of April 6, 2021 (the “Transaction Closing Date”). Effective as of the Transaction Closing Date, this Agreement
supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without
limitation the Executive Employment Agreement by and between the Executive and the Company, dated as of May 1, 2015, as amended (the “Prior
Agreement”); provided, however, that the Equity Documents (as defined below) shall continue to remain in effect, and,
further provided, that Section 2(g)(iii) below shall be effective as of the Effective Date.

 

WHEREAS, the Company desires to continue to employ
the Executive and the Executive desires to continue to be employed by the Company on the new terms and conditions contained herein.

 

NOW, THEREFORE, in consideration of the mutual
covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the parties agree as follows:

 

1.            
Employment.

 

(a)              
Term. The Company shall employ the Executive and the Executive shall be employed by the Company pursuant to this Agreement
commencing as of the Effective Date and continuing until such employment is terminated in accordance with the provisions hereof (the “Term”).
The Executive’s employment with the Company shall continue to be “at will,” meaning that the Executive’s employment
may be terminated by the Company or the Executive at any time and for any reason, subject to the terms of this Agreement.

 

(b)              
Position and Duties. The Executive shall serve as the President and Chief Executive Officer (“CEO”) of
the Company and shall have such powers and duties as may from time to time be prescribed by the Board of Directors (the “Board”).
The Executive shall devote the Executive’s full working time and efforts to the business and affairs of the Company. Notwithstanding
the foregoing, the Executive may serve on other boards of directors, subject to prior written approval of the Board, and engage in religious,
charitable or other community activities as long as such services on other boards of directors and activities do not interfere with the
Executive’s performance of the Executive’s duties to the Company.

 

2.            
Compensation and Related Matters.

 

(a)              
Base Salary. The Executive’s initial base salary shall be paid at the rate of $520,000 per year. The Executive’s
base salary shall be subject to periodic review by the Board or the Compensation Committee of the Board (the “Compensation Committee”).
The base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable
in a manner that is consistent with the Company’s usual payroll practices for its executive officers.

 

     

     

    

 

(b)              
Incentive Compensation. The Executive shall be eligible to receive cash incentive compensation as determined by the Board
or the Compensation Committee from time to time (the “Annual Bonus”). The Executive’s initial target annual incentive
compensation shall be fifty percent (50%) of the Executive’s Base Salary. The target annual incentive compensation in effect at
any given time is referred to herein as “Target Bonus.” The actual amount of the Executive’s annual incentive
compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any
applicable incentive compensation plan that may be in effect from time to time. Except as otherwise provided herein, as may be provided
by the Board or the Compensation Committee or as may otherwise be set forth in the applicable incentive compensation plan the Executive
must be employed by the Company on the date such incentive compensation is paid in order to earn or receive any annual incentive compensation.

 

(c)              
Transaction Bonuses. Subject to the Closing (as defined in the Merger Agreement) of the transactions as contemplated in
the Merger Agreement, the Executive shall be eligible to receive, upon the Transaction Closing Date, (i) a lump-sum cash transaction bonus
equal to $300,000 and (ii) a lump sum cash payment representing any Annual Bonus earned for FY 2020 in an amount equal to $260,000, each
of which shall be payable within 30 days of the Transaction Closing Date.

 

(d)              
Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive
during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the
Company for its executive officers.

 

(e)              
Other Benefits. The Executive shall be eligible to participate in or receive benefits under the Company’s employee
benefit plans in effect from time to time, subject to the terms of such plans.

 

(f)               
Paid Time Off. The Executive shall be entitled to take paid time off in accordance with the Company’s applicable paid
time off policy for executives, as may be in effect from time to time.

 

(g)              
Equity.

 

(i)                
The equity awards held by the Executive shall continue to be governed by the terms and conditions of the Company’s applicable
equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards (collectively, the “Equity
Documents”); provided, however, and notwithstanding anything to the contrary in the Equity Documents, Sections 5(c),
6(a) and 6(b)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause, by the Executive for Good
Reason, a Change in Control, or in connection with a Good Leaver Termination (if applicable), either outside or inside the Change in Control
Period (as such terms are defined below), as applicable.

 

    2

     

    

 

(ii)             
The Executive shall be eligible to participate in the Company’s 2021 Stock Option and Incentive Plan, as may be amended from
time to time (the “Plan”) and any successor plan thereto, on terms and conditions to be determined by the Board in
its discretion.

 

(iii)             
Subject to the approval of the Board and the execution of the Merger Agreement, the Executive will be granted an option to purchase
250,000 shares of the Company’s common stock (the “Option”) pursuant to, and subject to the terms and conditions
of, the Company’s 2020 Stock Option and Grant Plan and the Company’s form of Non-Qualified Stock Option Grant Notice. The
Option shall be granted at a per share exercise price equal to the fair market value of a share of Company common stock on the date of
grant and shall vest over four (4) years from the grant date as follows: twenty-five percent (25%) of the Option shall vest on the first
anniversary of the grant date with the remaining seventy-five percent (75%) vesting in thirty six (36) equal installments each month thereafter.

 

3.           
Termination. The Executive’s employment hereunder may be terminated without any breach of this Agreement under the
following circumstances:

 

(a)              
Death. The Executive’s employment hereunder shall terminate upon death.

 

(b)              
Disability. The Company may terminate the Executive’s employment if the Executive is disabled and unable to perform
or expected to be unable to perform the essential functions of the Executive’s then existing position or positions under this Agreement
with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question
shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s
then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall,
submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s
guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and
such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable
request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such
certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be
construed to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave
Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.

 

(c)              
Termination by the Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For
purposes of this Agreement, “Cause” shall mean any of the following:

 

    3

     

    

 

(i)               
conduct by the Executive constituting a material act of misconduct in connection with the performance of the Executive’s
duties, including, without limitation, (A) willful failure or refusal to perform material responsibilities that have been requested by
the Board; (B) dishonesty to the Board with respect to any material matter; or (C) misappropriation of funds or property of the Company
or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal
purposes;

 

(ii)              
the commission by the Executive of acts satisfying the elements of (A) any felony or (B) a misdemeanor involving moral
turpitude, deceit, dishonesty or fraud;

 

(iii)             
any misconduct by the Executive, regardless of whether or not in the course of the Executive’s employment, that would reasonably
be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if the Executive
were to continue to be employed in the same position;

 

(iv)            
continued non-performance by the Executive of the Executive’s duties hereunder (other than by reason of the Executive’s
physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such non-performance
from the Board;

 

(v)              
a breach by the Executive of any of the provisions contained in Section 8 of this Agreement or the Restrictive Covenants Agreement
(as defined below);

 

(vi)            
a material violation by the Executive of any of the Company’s written employment policies; or

 

(vii)            
the Executive’s failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement
authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other
materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other
materials in connection with such investigation.

 

(d)              
Termination by the Company without Cause. The Company may terminate the Executive’s employment hereunder at any time
without Cause. Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination
for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed
a termination without Cause.

 

(e)              
Termination by the Executive. The Executive may terminate employment hereunder at any time for any reason, including but
not limited to, Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has completed
all steps of the Good Reason Process (as defined below) following the occurrence of any of the following events without the Executive’s
consent (each, a “Good Reason Condition”):

 

(i)               
a material diminution in the Executive’s responsibilities, authority or duties;

 

    4

     

    

 

(ii)             
a material diminution in the Executive’s Base Salary except for across-the-board salary reductions based on the Company’s
financial performance similarly affecting all or substantially all senior management employees of the Company; or

 

(iii)             
a material breach of this Agreement by the Company.

 

The “Good Reason Process” consists of the following
steps:

 

(i)                
the Executive reasonably determines in good faith that a Good Reason Condition has occurred;

 

(ii)              
the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the first
occurrence of such condition;

 

(iii)             
the Executive cooperates in good faith with the Company’s efforts, for a period of not less than 30 days following such notice
(the “Cure Period”), to remedy the Good Reason Condition;

 

(iv)            
notwithstanding such efforts, the Good Reason Condition continues to exist at the end of the Cure Period; and

 

(v)              
the Executive terminates employment within 60 days after the end of the Cure Period.

 

If the Company cures the Good Reason Condition during the Cure Period,
Good Reason shall be deemed not to have occurred.

 

(f)               
Good Leaver Termination. The Executive may terminate the Executive’s employment hereunder at any time for any reason,
and such termination shall be deemed a Good Leaver Termination if all steps of the Good Leaver Process (as defined below) are completed.
For purposes of this Agreement, “Good Leaver Termination” shall mean that the Executive has continuously, and in good
standing, served in the role of President and CEO of the Company from the Effective Date of this Agreement until the first (1st)
anniversary of the Transaction Closing Date, and completed all steps of the Good Leaver Process. The “Good Leaver Process”
consists of the following steps:

 

(i)               
The Executive actively and in good faith participates in succession planning to identify and recruit a successor CEO of the Company
for a period of time beginning on the date the Executive provides the Company with a written Notice of Termination (as defined below)
(the “Good Leaver Notice Date”) and ending on the earlier of (i) the date that is six months following the Good Leaver
Notice Date, or (ii) the date that a candidate accepts an offer of employment with the Company as its successor CEO (the effective date
of such CEO termination, the “Good Leaver Termination Date”);

 

(ii)             
The Executive assists with the transition of duties to the Company’s successor CEO and, following onboarding, provides reasonable
business efforts in an individual contributor capacity for a six-month period following the Good Leaver Notice Date; and

 

    5

     

    

 

(iii)             
Promptly following the Good Leaver Termination Date, the Executive returns all company property and confidential information.

 

4.            
Matters related to Termination.

 

(a)              
Notice of Termination. Except for termination as specified in Section 3(a), any termination of the Executive’s employment
by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto.
For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination
provision in this Agreement relied upon.

 

(b)              
Date of Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated
by death, the date of death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by
the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment
is terminated by the Company without Cause under Section 3(d), the date on which a Notice of Termination is given or the date otherwise
specified by the Company in the Notice of Termination; (iv) if the Executive’s employment is terminated by the Executive under Section
3(e) other than for Good Reason or a Good Leaver Termination, 30 days after the date on which a Notice of Termination is given, (v) if
the Executive’s employment is terminated by the Executive under Section 3(e) for Good Reason, the date on which a Notice of Termination
is given after the end of the Cure Period, and (vi) if the Executive’s employment is terminated by the Executive under Section 3(f)
as a Good Leaver Termination, the Good Leaver Termination Date. Notwithstanding the foregoing, in the event that the Executive gives a
Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not
result in a termination by the Company for purposes of this Agreement.

 

(c)              
Accrued Obligations. If the Executive’s employment with the Company is terminated for any reason, the Company shall
pay or provide to the Executive (or to the Executive’s authorized representative or estate) (i) any Base Salary earned through the
Date of Termination and, if applicable, any accrued but unused vacation through the Date of Termination; (ii) unpaid expense reimbursements
(subject to, and in accordance with, Section 2(d) of this Agreement); and (iii) any vested benefits the Executive may have under any employee
benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the
terms of such employee benefit plans (collectively, the “Accrued Obligations”).

 

(d)              
Resignation of All Other Positions. To the extent applicable, the Executive shall be deemed to have resigned from all officer
and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination
of the Executive’s employment for any reason. The Executive shall execute any documents in reasonable form as may be requested to
confirm or effectuate any such resignations.

 

    6

     

    

 

5.            
Severance Pay and Benefits Upon Termination by the Company without Cause, Upon Resignation by the Executive for Good Reason,
or Upon a Good Leaver Termination, in each case Outside the Change in Control Period. If the Executive’s employment is terminated
by the Company without Cause as provided in Section 3(d) or the Executive terminates employment for Good Reason as provided in Section
3(e), in each case outside of the Change in Control Period (as defined below), or if the Executive’s employment is terminated upon
a Good Leaver Termination at any time as provided in Section 3(f), then, in addition to the Accrued Obligations, and subject to (i) the
Executive signing a separation agreement and release in a form and manner satisfactory to the Company, which shall include, without limitation,
a general release of claims against the Company and all related persons and entities that shall not release the Executive’s rights
under this Agreement, a reaffirmation of all of the Executive’s Continuing Obligations (as defined below), and shall provide
that if the Executive breaches any of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the “Separation
Agreement”), and (ii) the Separation Agreement becoming irrevocable, all within 60 days after the Date of Termination (or such
shorter period as set forth in the Separation Agreement), which shall include a seven (7) day revocation period:

 

(a)              
the Company shall pay the Executive an amount equal to 12 months of the Executive’s Base Salary (the “Severance
Amount”);

 

(b)              
subject to the Executive’s copayment of premium amounts at the applicable active employees’ rate and the Executive’s
proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”),
the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the monthly employer contribution
that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until
the earliest of (A) the 12 month anniversary of the Date of Termination; (B) the date that the Executive becomes eligible for group medical
plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s health continuation rights
under COBRA; provided, however, that if the Company determines that it cannot pay such amounts to the group health plan provider
or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the
Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period
specified above. Such payments to the Executive shall be subject to tax-related deductions and withholdings and paid on the Company’s
regular payroll dates; and

 

(c)              
notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, a number of shares
pursuant to each stock-based awards held by the Executive subject solely to:

 

(i)               
 time-based vesting (the “Time-Based Equity Awards”) equal to the number of shares that would have vested pursuant
to such Time-Based Equity Award during the six-month period immediately following the Date of Termination had the Executive remained in
continuous employment with the Company during such period, will immediately vest and become exercisable as of the Date of Termination;
and

 

    7

     

    

 

(ii)              
performance-based vesting (the “Performance-Based Equity Awards” and together with the Time-Based Equity Awards, the
 “Outstanding Equity Awards”) equal to the number of shares that would have vested pursuant to such Performance-Based
Equity Awards subject to the Company’s achievement of the applicable performance-based vesting conditions described therein within
the six-month period following the Date of Termination, provided that any termination or other forfeiture of the unvested portion of the
applicable Performance-Based Equity Award(s) that would otherwise occur on the Date of Termination in the absence of a Good Leaver Termination
will be delayed to effect the terms of this Section 5(c)(ii) and such termination will subsequently occur if the vesting pursuant to this
subsection does not occur due to the absence of the Separation Agreement becoming fully effective within the time period set forth therein
and the failure of the Company to achieve the applicable performance-based vesting conditions during the six-month period following the
Date of Termination.

 

The amounts payable pursuant to this Section 5, to
the extent taxable, shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over
12 months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar
year and ends in a second calendar year, such payments, to the extent they qualify as “non-qualified deferred compensation”
within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), shall begin to be
paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include
a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this
Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).

 

6.            
Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason within the Change
in Control Period. The provisions of this Section 6 shall apply in lieu of, and expressly supersede, the provisions of Section 5 if
a Change in Control occurs and if (i) the Executive’s employment is terminated either (a) by the Company without Cause as provided
in Section 3(d), or (b) by the Executive for Good Reason as provided in Section 3(e), and (ii) the Date of Termination is within 12 months
after the occurrence of the first event constituting a Change in Control (such period, the “Change in Control Period”).
For the avoidance of doubt, this Section 6 shall terminate and be of no further force or effect after the Change in Control Period.

 

(a)              
Upon the consummation of a Change in Control and subject to Executive’s continued employment with the Company through such
date, all Performance-Based Equity Awards will convert to Time-Based Equity Awards at Target without proration, which shall vest in substantially
equal monthly installments each month following the consummation of such Change in Control over (i) the remainder of the applicable performance
period set forth in the underlying award agreement, or (ii) twenty-four (24) consecutive months following the consummation of such Change
in Control, if no such performance period is contained in the underlying award agreement and, in each case of (i) and (ii), such Outstanding
Equity Awards shall be eligible for the treatment as described in 6(b)(ii) below.

 

    8

     

    

 

(b)              
If the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates
employment for Good Reason as provided in Section 3(e) and in each case the Date of Termination occurs during the Change in Control Period,
then, in addition to the Accrued Obligations, and subject to the signing of a general release of claims against the Company and all related
persons and entities that shall not release the Executive’s rights under this Agreement (the “Release”) by the
Executive and the Release becoming fully effective, all within the time frame set forth in the Release but in no event more than 60 days
after the Date of Termination:

 

(i)                
the Company shall pay the Executive a lump sum in cash in an amount equal to two times the sum of (A) the Executive’s then-current
Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B) the Executive’s
Target Bonus for the then-current year (or the Executive’s Target Bonus in effect immediately prior to the Change in Control, if
higher);

 

(ii)             
notwithstanding anything to the contrary in any applicable Outstanding Equity Award Agreement, all Outstanding Equity Awards held
by Executive shall immediately accelerate and become fully vested and exercisable or nonforfeitable as of the later of (i) the Date of
Termination or (ii) the effective date of the Release (the “Accelerated Vesting Date”), provided that in order
to effectuate the accelerated vesting contemplated by this subsection, the unvested portion of the Executive’s Outstanding Equity
Awards that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A) the effective date of the
Release (at which time acceleration will occur), or (B) the date that the Release can no longer become fully effective (at which time
the unvested portion of the Executive’s Outstanding Equity Awards will be forfeited); and

 

(iii)             
subject to the Executive’s copayment of premium amounts at the applicable active employees’ rate and the Executive’s
proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider or the COBRA provider a monthly
payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the
Executive had remained employed by the Company until the earliest of (A) the 24 month anniversary of the Date of Termination; (B) the
date that the Executive becomes eligible for group medical plan benefits under any other employer’s group medical plan; or (C) the
cessation of the Executive’s health continuation rights under COBRA; provided, however, that if the Company determines that
it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable
law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll
payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to tax-related
deductions and withholdings and paid on the Company’s regular payroll dates.

 

The amounts payable under this Section 6(b), to the
extent taxable, shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the
60-day period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as “non-qualified
deferred compensation” within the meaning of Section 409A of the Code, shall be paid or commence to be paid in the second calendar
year by the last day of such 60-day period.

 

    9

     

    

 

(c)              
Additional Limitation.

 

(i)               
Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution
by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of
this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code, and the applicable regulations thereunder
(the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate
Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at
which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only
occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the
Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order,
in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation
of the transaction that is subject to Section 280G of the Code: (1) cash payments not subject to Section 409A of the Code; (2) cash payments
subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that
in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1,
Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b)
or (c).

 

(ii)              
For purposes of this Section 6(b), the “After Tax Amount” means the amount of the Aggregate Payments less all
federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive’s receipt of
the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at
the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to
be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality,
net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.

 

(iii)            
The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 6(b)(i) shall be made by
a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed
supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at
such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding
upon the Company and the Executive.

 

    10

     

    

 

(d)              
Change in Control. For purposes of this Section 6, “Change in Control” shall mean a Sale Event as defined
in the 2020 Stock Option and Grant Plan and the successor plan thereto once adopted, provided that a Sale Event will not be deemed to
have occurred solely due to the Closing of the transactions contemplated by the Merger Agreement or any other capital raising transaction.

 

7.            
Section 409A.

 

(a)              
Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within
the meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning
of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement
or otherwise on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to
the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i)
of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months
and one day after the Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment
is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise
have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable
in accordance with their original schedule.

 

(b)              
All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or
incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively
practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which
the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect
the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other
aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or
exchange for another benefit.

 

(c)              
To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation”
under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment,
then such payments or benefits shall be payable only upon the Executive’s “separation from service.” The determination
of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation
Section 1.409A-1(h).

 

(d)              
The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any
provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner
so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants
Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that
this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the
Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to
either party.

 

    11

     

    

 

(e)              
The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions
of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption
from, or the conditions of, such Section.

 

8.            
Continuing Obligations.

 

(a)              
Restrictive Covenants Agreement. As a condition of continued employment and other consideration provided to Executive herein,
the Executive is required to enter into the Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement, attached
hereto as Exhibit A (the “Restrictive Covenants Agreement”). For purposes of this Agreement, the obligations in this
Section 8 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment
of inventions, or other restrictive covenants shall collectively be referred to as the “Continuing Obligations.”

 

(b)              
Third-Party Agreements and Rights. The Executive hereby confirms that the Executive is not bound by the terms of any agreement
with any previous employer or other party which restricts in any way the Executive’s use or disclosure of information, other than
confidentiality restrictions (if any), or the Executive’s engagement in any business. The Executive represents to the Company that
the Executive’s execution of this Agreement, the Executive’s employment with the Company and the performance of the Executive’s
proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party.
In the Executive’s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements
with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies
or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.

 

(c)              
Litigation and Regulatory Cooperation. During and after the Executive’s employment, the Executive shall cooperate
fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future
against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company,
and (ii) the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge
or information. The Executive’s full cooperation in connection with such claims, actions or investigations shall include, but not
be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on
behalf of the Company at mutually convenient times. During and after the Executive’s employment, the Executive also shall cooperate
fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such
investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company
shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance
of obligations pursuant to this Section 8(c).

 

    12

     

    

 

(d)              
Relief. The Executive agrees that it would be difficult to measure any damages caused to the Company which might result
from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for
any such breach. Accordingly, the Executive agrees that if the Executive breaches, or proposes to breach, any portion of the Continuing
Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate
equitable relief to restrain any such breach without showing or proving any actual damage to the Company.

 

9.            
Reserved.

 

10.           
Consent to Jurisdiction. The parties hereby consent to the jurisdiction of the state and federal courts of the State of
Delaware. Accordingly, with respect to any such court action, the Executive (a) submits to the exclusive personal jurisdiction of such
courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise)
with respect to personal jurisdiction or service of process.

 

11.          
Waiver of Jury Trial. To the extent permitted by applicable law, each of the Executive and the Company irrevocably and unconditionally
waives all right to trial by jury in any Proceeding (whether based on contract, tort or otherwise)
arising out of or relating to this Agreement or THE EXECUTIVE’s employment by the Company or any affiliate of the Company, INCLUDING
WITHOUT LIMITATION THE EXECUTIVE’S or the Company’s performance under, or the enforcement of, this Agreement. 

 

12.          
Integration. Effective as of the Transaction Closing Date, this Agreement constitutes the entire agreement between the parties
with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, including
the Prior Agreement, provided that the Equity Documents remain in full force and effect.

 

13.          
Withholding; Tax Effect. All payments made by the Company to the Executive under this Agreement shall be net of any tax
or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require
the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or benefits or for
any deduction or withholding from any payment or benefit.

 

14.          
Assignment; Successors and Assigns. Neither the Executive nor the Company may make any assignment of this Agreement or any
interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company
may assign its rights and obligations under this Agreement (including the Restrictive Covenants Agreement) without the Executive’s
consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into
which the Company merges or to whom it transfers all or substantially all of its properties or assets; provided, further that if
the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such
transaction, then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Sections 5 or 6 of this Agreement
solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon the Executive and the Company,
and each of the Executive’s and the Company’s respective successors, executors, administrators, heirs and permitted assigns.
In the event of the Executive’s death after the Executive’s termination of employment but prior to the completion by the Company
of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive’s beneficiary
designated in writing to the Company prior to the Executive’s death (or to the Executive’s estate, if the Executive fails
to make such designation).

 

    13

     

    

 

15.          
Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of
any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the
remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared
illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable
to the fullest extent permitted by law.

 

16.          
Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the
Executive’s employment to the extent necessary to effectuate the terms contained herein.

 

17.         
Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The
failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach
of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

 

18.          
Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in
writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage
prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the
case of the Company, at its main offices, attention of the Board.

 

19.          
Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly
authorized representative of the Company.

 

20.          
Effect on Other Plans and Agreements. An election by the Executive to resign for Good Reason under the provisions of this
Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of
any of the Company’s benefit plans, programs or policies. Nothing in this Agreement shall be construed to limit the rights of the
Executive under the Company’s benefit plans, programs or policies except as otherwise provided in Section 8 hereof, and except that
the Executive shall have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. In the event
that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and under
this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both.
Further, Section 5 and Section 6 of this Agreement are mutually exclusive and in no event shall the Executive be entitled to payments
or benefits pursuant to both Sections 5 6 of this Agreement.

 

    14

     

    

 

21.          
Governing Law. This is a Delaware contract and shall be construed under and be governed in all respects by the laws of the
State of Delaware, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law,
such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals
for the Third Circuit.

 

22.          
Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered
shall be taken to be an original; but such counterparts shall together constitute one and the same document.

 

IN WITNESS WHEREOF, the parties have executed this
Agreement effective on the Effective Date.

 

	 	BETTER THERAPEUTICS, INC.
	 	 
	 	By:	/s/ David Perry
	 	Its:	Executive Chairman
	 	 
	 	EXECUTIVE
	 	 
	 	/s/ Kevin Appelbaum
	 	Kevin Appelbaum

 

    15

     

    

 

Exhibit A

Restrictive Covenants Agreement

 

[Omitted]Exhibit
4.3

 

Description
of Securities

 

The
following description is intended as a summary and is qualified in its entirety by reference to our Restated Certificate of Incorporation,
as amended (the “Certificate of Incorporation”) and our Amended and Restated By-Laws (the “By-laws”) as currently
in effect, copies of which are filed as exhibits to this Amendment No. 1 to the Annual Report on Form 10-K and are incorporated
by reference herein.

 

Authorized
Capital Stock

 

As
of December 31, 2020, we have authorized 42,499,999 shares of capital stock, par value $0.001 per share, of which 41,666,666 are shares
of common stock and 833,333 are shares of “blank check” preferred stock, par value $0.01 per share, of which 50,000 are authorized
as Series B Junior Participating Preferred Stock. As of March 23, 2021, there were 36,780,038 shares of common stock issued and
outstanding and no shares of preferred stock issued and outstanding. We have reserved all of the shares of our Series B Junior Participating
Preferred Stock for issuance upon the exercise of the rights under our Shareholder Protection Rights Agreement described below. The authorized
and unissued shares of common stock and the authorized and undesignated shares of preferred stock are available for issuance without
further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our
securities may be listed. Unless approval of our stockholders is so required, our board of directors does not intend to seek stockholder
approval for the issuance and sale of our common stock or preferred stock.

 

Common
Stock

 

Holders
of our common stock are entitled to one vote per share on matters on which our stockholders vote, including with respect to the election
of directors. Holders of common stock are entitled to receive dividends, if declared by our board of directors, out of funds that we
may legally use to pay dividends. If we liquidate or dissolve, holders of common stock are entitled to share ratably in our assets once
our debts and any liquidation preference owed to holders of any then-outstanding preferred stock are paid. All shares of common stock
that are outstanding as of the date of this report are fully-paid and nonassessable. Holders of our common stock have no preemptive,
conversion or subscription rights, and there are no redemption or sinking fund provisions with respect to our common stock.

 

Preferred
Stock

 

The
board of directors is authorized, subject to any limitations prescribed by law, without further vote or action by the stockholders, to
issue from time to time shares of preferred stock in one or more series. Each such series of preferred stock shall have such number of
shares, designations, preferences, voting powers, qualifications, and special or relative rights or privileges as shall be determined
by the board of directors, which may include, among others, dividend rights, voting rights, liquidation preferences, conversion rights
and preemptive rights. Issuance of preferred stock by our board of directors may result in such shares having dividend and/or liquidation
preferences senior to the rights of the holders of our common stock and could dilute the voting rights of the holders of our common stock.

 

Series
B Junior Participating Preferred Stock

 

Each
share of the Series B Junior Participating Preferred Stock is entitled to receive, when, as and if declared by the board of directors
out of funds legally available for that purpose, quarterly dividends payable in cash on the last day of February, May, August, and December
in each year (each such date being a “Quarterly Dividend Payment Date”), in an amount per share (rounded to the nearest cent)
equal to the greater of (a) $1.00 or (b) subject to certain adjustments, 1,000 times the aggregate per share amount of all cash dividends
declared on shares of the common stock since the immediately preceding Quarterly Dividend Payment Date, and, subject to certain adjustments,
quarterly distributions (payable in kind) on each Quarterly Dividend Payment Date in an amount per share equal to 1,000 times the aggregate
per share amount of all non-cash dividends or other distributions (other than a dividend payable in shares of common stock or a subdivision
of the outstanding shares of common stock, by reclassification or otherwise) declared on shares of common stock since the immediately
preceding Quarterly Dividend Payment Date. The terms of the Series B Junior Participating Preferred Stock were amended on November 12,
2020. The description herein reflects such amended terms.

 

    	 

    	 

    

 

In
the event of our liquidation or winding up of affairs, no distribution shall be made to the holders of shares of stock junior to Series
B Junior Participating Preferred Stock, including common stock, unless the holders of shares of Series B Junior Participating Preferred
Stock shall have received, the greater of either (a) $1.00 per share plus an amount equal to accrued and unpaid dividends and distributions
thereon, whether or not declared, to the date of such payment, or (b) the amount equal to 1,000 times the aggregate per share amount
to be distributed to holders of shares of common stock, or to the holders of shares ranking pari passu with the Series B Preferred
Stock, unless simultaneously therewith distributions are made ratably on shares of Series B Junior Participating Preferred Stock and
all other shares of such pari passu shares in proportion to the total amounts to which the holders of shares of Series B Junior
Participating Preferred Stock are entitled under clause (a) of this sentence and to which the holders of such pari passu shares
are entitled, in each case upon such liquidation, dissolution or winding up.

 

If
at any time dividends on any shares of Series B Junior Participating Preferred Stock are in arrears in an amount equal to six quarterly
dividends, then the number of directors constituting the board of directors shall automatically be increased by two, and during the period
(a “default period”) from such time until the time when all accrued and unpaid dividends for all previous quarterly dividend
periods and for the current quarterly dividend period on all shares of Series B Junior Participating Preferred Stock have been declared
and paid, the holders of the outstanding shares of Series B Junior Participating Preferred Stock, together with the holders of outstanding
shares of any one or more other series of preferred stock entitled to like voting rights (voting together as a single class), shall have
the right to elect two directors to the board of directors at our next annual meeting of stockholders, and may elect a successor to each
of the two directors so long as such default period continues.

 

Anti-Takeover
Law and Provisions of our Certificate of Incorporation and By-laws

 

Section
203 of the Delaware General Corporation Law is applicable to takeovers of certain Delaware corporations, including us. Subject to exceptions
enumerated in Section 203, Section 203 provides that a corporation shall not engage in any business combination with any “interested
stockholder” for a three-year period following the date that the stockholder becomes an interested stockholder unless:

 

	 	●	prior
    to that date, the board of directors of the corporation approved either the business combination or the transaction that resulted
    in the stockholder becoming an interested stockholder;

 

	 	●	upon
    consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned
    at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, though some shares may be
    excluded from the calculation; or

 

	 	●	on
    or subsequent to that date, the business combination is approved by the board of directors of the corporation and by the affirmative
    votes of holders of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder. 

 

The
term “business combination” is defined to include, among other transactions between an interested stockholder and a corporation
or any direct or indirect majority owned subsidiary thereof: a merger or consolidation; a sale, lease, exchange, mortgage, pledge, transfer
or other disposition (including as part of a dissolution) of assets having an aggregate market value equal to 10% or more of either the
aggregate market value of all assets of the corporation on a consolidated basis or the aggregate market value of all the outstanding
stock of the corporation; certain transactions that would result in the issuance or transfer by the corporation of any of its stock to
the interested stockholder; certain transactions that would increase the interested stockholder’s proportionate share ownership
of the stock of any class or series of the corporation or such subsidiary; and any receipt by the interested stockholder of the benefit
of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation or any such subsidiary.

 

    	 

    	 

    

 

Except
as specified in Section 203, an interested stockholder is generally defined to include any person who, together with any affiliates or
associates of that person, beneficially owns, directly or indirectly, 15% or more of the outstanding voting stock of the corporation,
or is an affiliate or associate of the corporation and was the owner of 15% or more of the outstanding voting stock of the corporation,
any time within three years immediately prior to the relevant date. Under certain circumstances, Section 203 makes it more difficult
for an interested stockholder to effect various business combinations with a corporation for a three-year period, although the stockholders
may elect not to be governed by this section, by adopting an amendment to the Certificate of Incorporation or the By-laws, effective
12 months after adoption. Our Certificate of Incorporation and By-laws do not opt out from the restrictions imposed under Section 203.
We anticipate that the provisions of Section 203 may encourage companies interested in acquiring us to negotiate in advance with the
board of directors because the stockholder approval requirement would be avoided if a majority of the directors then in office excluding
an interested stockholder approve either the business combination or the transaction that resulted in the stockholder becoming an interested
stockholder. These provisions may have the effect of deterring hostile takeovers or delaying changes in control, which could depress
the market price of our common stock and deprive stockholders of opportunities to realize a premium on shares of common stock held by
them.

 

Certificate
of Incorporation and By-Law Provisions

 

In
addition to the board of directors’ ability to issue shares of preferred stock, our Certificate of Incorporation and By-laws contain
the following provisions that may have the effect of discouraging unsolicited acquisition proposals:

 

	 	●	our By-laws
    classify the board of directors into three classes with staggered three-year terms;
	 	 	 
	 	●	under our By-laws, our
    board of directors may enlarge the size of the board and fill the vacancies;
	 	 	 
	 	●	our By-laws provide that
    a stockholder may not nominate candidates for the board of directors at any annual or special meeting unless that stockholder notifies
    us of its intention a specified period in advance and provides us with certain required information;
	 	 	 
	 	●	stockholders who wish to
    bring business before the stockholders at our annual meeting must provide advance notice;
	 	 	 
	 	●	our By-laws provide that
    stockholders may only act by written consent in lieu of a meeting if such consent is unanimous; and
	 	 	 
	 	●	our By-laws provide that
    special meetings of stockholders may only be called by our board of directors or by an officer so instructed by our board.

 

Our
By-laws also provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State
of Delaware will be the sole and exclusive forum for:

 

	 	●	any derivative
    action or proceeding brought on our behalf;
	 	 	 
	 	●	any action asserting a
    claim of breach of a fiduciary duty owed by any director, officer or other employee of the company to us or our stockholders;
	 	 	 
	 	●	any action asserting a
    claim arising pursuant to any provision of the Delaware General Corporation Law; or
	 	 	 
	 	●	any action asserting a
    claim governed by the internal affairs doctrine.

 

Our
By-laws further provide that any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the company
is deemed to have notice of and consented to the foregoing provision.

 

    	 

    	 

    

 

Shareholder
Protection Rights Agreement

 

On
December 13, 2019, our board of directors, authorized and declared a dividend of one right (a “Right”) for each of our issued
and outstanding shares of common stock. The dividend was paid to the stockholders of record at the close of business on December 23,
2019. Each Right entitled the registered holder, subject to the terms of the Original Rights Agreement (as defined below), to purchase
from us one one-thousandth of a share of our Series B Junior Participating Preferred Stock, par value $0.01 per share (the “Preferred
Stock”), at a price of $5.00 (the “Purchase Price”), subject to certain adjustments. The description and terms of the
Rights were set forth in the Rights Agreement, dated as of December 13, 2019 (the “Original Rights Agreement”), by and between
us and American Stock Transfer & Trust Company, LLC, as Rights Agent (the “Rights Agent”).

 

On
November 12, 2020, the board of directors approved an amendment and restatement of the Original Rights Agreement (as amended and restated,
the “Amended and Restated Rights Agreement”) to effect certain changes to the Original Rights Agreement, including (i) reducing
the duration to a term of three years, subject to certain earlier expiration as described in more detail below, and (ii) lowering the
beneficial ownership threshold at which a person or group of persons becomes an Acquiring Person (as defined below) to 4.95% or more
of our outstanding shares of common stock, subject to certain exceptions. The Amended and Restated Rights Agreement is designed to discourage
(i) any person or group of persons from acquiring beneficial ownership of more than 4.95% of our shares of common stock and (ii) any
existing stockholder currently beneficially holding 4.95% or more of our shares of common stock from acquiring additional shares of our
common stock.

 

The
purpose of the Amended and Restated Rights Agreement is to protect value by preserving the Company’s ability to utilize its net
operating losses and certain other tax attributes (collectively, the “Tax Benefits”) to offset potential future income tax
obligations. Our ability to use our Tax Benefits would be substantially limited if it experiences an “ownership change,”
as such term is defined in Section 382 of the Internal Revenue Code of 1986, as amended (the “Tax Code”). A corporation generally
will experience an ownership change if the percentage of the corporation’s stock owned by its “5-percent shareholders,”
as defined in Section 382 of the Tax Code, increases by more than 50 percentage points over their lowest ownership percentage within
a rolling three-year period. The Amended and Restated Rights Agreement is intended to reduce the likelihood we would experience an ownership
change under Section 382 of the Tax Code. The rights are only exercisable upon the occurrence of certain triggering events described
in the Amended and Restated Rights Agreement.

 

Transfer
Agent

 

The
transfer agent for our common stock is American Stock Transfer & Trust Co. The transfer agent’s address is 40 Wall Street,
New York, New York 10005.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]